ADMA Biologics ADMA Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's change in accrued liabilities?
- ADMA Biologics (ADMA) reported change in accrued liabilities of $5.11M in Q1 2026.
- How has ADMA Biologics's change in accrued liabilities changed year-over-year?
- ADMA Biologics's change in accrued liabilities increased by 312.6% year-over-year, from -$2.4M to $5.11M.
- What is the long-term trend for ADMA Biologics's change in accrued liabilities?
- Over 4 years (2021 to 2025), ADMA Biologics's change in accrued liabilities has grown at a -11.1% compound annual growth rate (CAGR), from $8.34M to $5.21M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.